Inhibitors of RNR such hydroxurea and gemcitabine are clinically-validated antimetabolites used in cancer treatment and have been reported induce Chk1 S345 and Chk2 T68 phosphorylation [12], [40]. Here, CHEK1 is linked to cancer.